BioStem's Q4-2024 revenue expected to rise 794% YoY, with full-year net revenue increasing 1,702%. Read why I'm bullish on BSEM stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback